

Intelligence.  
Beautifully engineered.



Confidential and proprietary: Any use of this material without specific permission of McKinsey & Company is strictly prohibited



# 1896 Olympic Games, Athens – 100m





# 2016 Olympic Games, Rio – 100m



In elite sport the  
smallest edge makes  
the difference,  
and the best teams  
exploit this to outlearn  
their rivals



2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.



2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.



# Arms race in innovation

Data has emerged as a fundamental element of competitive advantage

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.



2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.





# Why now?

Better algorithms



Better GPUs



Cloud




More data






Technology revolutions tend to involve an important activity becoming much cheaper





# Machine intelligence radically reduces cost of discovery





# We expect *Augmented Intelligence* to be applied in waves ...



## Wave 1

**Apply to things we've always done**

- Weather
- Sales
- Maintenance

## Wave 2

**Apply to things we couldn't do before**

- Autonomous vehicles
- Hospital operations
- Real-world evidence

## Wave 3


**Reimagine the core operating process**

- Product development
- Organization design
- Business model

# Early adopters become serial adopters

AI Index

Relatively low  Relatively high





# Applying this in the real world.

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.


2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

# Re-engineering the product development process






# Linked and cleaned the previously unlinked datasets



# Data offers different perspectives





# The car as a network



# Explanatory model to understand drivers of performance...

TOTAL OPPORTUNITY

OPPORTUNITY

DRIVER



58.7  
Days

TEAM  
DYNAMICS



23.1  
Days

PROCESS DESIGN/  
ADHERENCE



8.9  
Days

SOURCING &  
SUPPLYING



7  
Days

ITERATIONS/  
REVISIONS




## Explanatory

Modelling technique  
using **Linear Regression**  
to arrive at insight




# ...which, in turn, allow precise interventions

- One such factor we uncovered was the significance of aligning the way designers and engineers communicate, and work together
- Because engineers were not waiting for final design sign off before iterating components, time and money was being lost



# Reimagining the core operating system of the firm





# The opportunity in MedTech.


2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

# Advanced analytics can significantly improve efficiency and drive impact across the value chain in MedTech



## Illustrative impact we have seen





# A Predict what is driving speed of enrollment, costs and quality of clinical trials



**300m**

Integrated 300 million data entries of so far disconnected internal trial data (Trial Management, Quality, Finance, HR, etc.) with external data (Rx/claims, publications, etc.) into a rich data lake and used predictive algorithms to forecast site-level patient recruitment and quality events

**10-20%**

Faster enrollment

**10-15%**

Lower trial costs

**5x**

Better targeting of site level audits

## B Understanding what is driving sales performance



20

Integrated data sets that the firm had never previously linked, including many it had never used at all, such as CRM, e-mails, and patient diagnostic data

25%

Faster initiation of first sale

10%

Increase in sales from avoiding dormant accounts



< Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr >

||  
Pause

×

State

WI (3D) ▾

Edges represent:

All Patients ▾

Options

- ☒ Show Nodes
- ☒ Show Edges
- ☒ Auto-rotate

Jul 2015

0 / 4515 Physicians Converted

Nodes: Converted?



Edges: All Patients (Shared)





Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr

May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar



Play

## State

KY

## Edges represent:

All Patients

## Options

- ☒ Show Nodes
- ☒ Show Edges

Apr 2017

506 / 4441

Physicians Converted

Nodes: Converted?



x


✓

Edges: All Patients (Shared)




0

500





## C Identify clinically and commercially relevant patient segments in which drug has better efficacy and cost profile than competitors



### 65m

Detailed 10 years of EMR & claims data with 65mn patients Available now, & everyone can access

Replicated findings from previous research to show robustness of the approach and data

### 58%

Identified 4 clinically relevant patient segments where drug meaningfully outperforms competitors — segments together cover 58% of patient population

Live interactive tool deployed for cross-functional team to explore patient segments and build actionable clusters

Efficacy: ☒ All adverse events ☐ Effective adverse events


Bubble size

- ☒ No. of Drug B patients
- ☐ Total cost per adverse event
- ☐ Incremental adverse-event-related cost per patient

Legend



Patient segments: Drug A vs. Drug B



Segments

Search list

Drug A outperforms Drug B, and performs better than average

Male patients

Obese patients

Patients aged  $\geq 53$  and  $< 61$  years at treatment start

Patients aged  $\geq 61$  and  $< 70$  years at treatment start

Patients aged  $< 53$  years at treatment start

Patients in regions with  $\geq 23\%$  and  $< 26\%$  college education rates

All Patients

No. of patients - Drug B



Incurred incremental cost (pppy)



Incurred cost (per adverse event)



Adverse event rate differential (pppy)



Adverse event rate by efficacy (pppy)





## D Reducing service cost of MRI scanners with analytic troubleshooting & condition based maintenance



**50,000**

Unique instrument with 1GB per instrument plus 10 years service data

**25%**

Predicts common service events 90 days ahead of time

**\$300m**

Saving opportunity of \$35m/yr in North America and \$300m/yr globally

## E Developing service to increase theatre utilisation without compromising quality



800k

Procedures across  
16 hospitals over 8  
years

35%

Improvement in  
procedure  
forecasting

12%

Increase in theatre  
suite utilisation



# Lessons and scars.

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

# Patterns we've spotted along the way

## 1

### Start with what you have

- Leveraging latent internal and external data as an asset; think of 'edge data'
- Embrace the taboo of 'garbage' data, instead invest in data provenance
- Variety more important than volume, so invest in 'machine readable' connectivity

## 2

### Build feedback loops

- Focus on using your data to help you continuously improve
- Instrument everything; your process, your product, your people
- Capturing, interpreting and exploiting data at scale and at pace to outlearn your rivals

## 3

### Build capabilities not models

- It's not about the analytics; it's how you embed them into the operating model
- Cascade performance driven use case to benefit from 'network effects'
- Leaders invest in 5 building blocks: data & analytics, IT, process (incl. action and judgment), governance, and people / culture



# Making it happen.

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

# 'Winners' have taken a few critical decisions to lay the foundation

■ Detailed on next page

## Reporting lines, policies, standards

- How to structure the analytics function?
- Will we enforce global standards?

## External data partnerships, data lakes

- How do we design win-win partnerships with distinctive data providers?
- What do we need to consider regarding legal and privacy requirements?
- How do we tackle data security?

## Business/IT interactions, internal processes in analytics "function"

- Do we create new analytics business partner roles?
- How do we design processes to be as agile as possible?
- What business processes need to be adapted which ones automated?

## Governance



## People

## Talent, skills

- What skills gaps do we fill in first?
- How do we attract & retain talent?
- How do we manage change?

## Analytics


## Analytics, data mgmt., visualization platforms/tools

- What global platforms do we build as enterprise capabilities?
- What does this imply for the existing system landscape?
- What is the role of cloud-sourcing?
- How shall data be visualized?

## Data



## IT



## Process



# Data: new paradigm needed

## From

**Data as by-product** of the corporation to be managed internally

**Traditional warehouse structured process** to implement new data elements

**“Boring data”** (e.g., structured, internal, and centralized data)

**Receive dos and don'ts from legal**

**Local data access** restricted by physical location (e.g., home office desktop)

## To

**Data that can be acquired or created** (e.g., sensors, public application, interfaces, crowd-surfing)

**Test-and-learn** “data lakes” environment to make data available quickly

**Diverse data** (e.g., unstructured external and distributed data)

**Really understand and actively shape corporate policies**

**“Democratization” of data while keeping data security** in any location, time, or device (e.g., iPad)

New data sources



Orchestration of data



Unstructured data



Privacy and legal considerations




Data security





# People: new capabilities needed



Forget about  
perfection, focus on  
progression and  
compound the  
improvement

Sir David Brailsford, CBE



Thank you.  
Q&A.

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.

2018 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited.